Summary
The NABUCCO trial investigated preoperative combination checkpoint inhibitor therapy (ipilimumab plus nivolumab) at two dose levels in patients with stage III urothelial cancer. As suggested by the trial design, the study compared safety profiles and efficacy outcomes between high and low-dose regimens to inform optimal dosing strategies for neoadjuvant immunotherapy in this indication.
UK applicability
As a phase 1B trial in urothelial cancer, the findings may inform UK oncology practice guidelines and NHS treatment pathways for bladder cancer patients, though adoption would depend on cost-effectiveness assessment and integration with existing surgical protocols within UK cancer networks.
Key measures
Adverse events, dose-limiting toxicities, pathological complete response rates, major pathological response rates, recurrence-free survival
Outcomes reported
The study evaluated safety, tolerability, and efficacy of two dose regimens of combined ipilimumab and nivolumab as neoadjuvant therapy in stage III urothelial cancer patients prior to surgical resection.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.